phenyl N-(imidazo[1,2-a]pyridin-8-yl)carbamate | 1229383-39-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: phenyl N-(imidazo[1,2-a]pyridin-8-yl)carbamate
• 英文别名: imidazo[1,2-a]pyridin-8-yl-carbamic acid phenyl ester；phenyl N-imidazo[1,2-a]pyridin-8-ylcarbamate
• CAS: 1229383-39-4
• 化学式: C₁₄H₁₁N₃O₂
• 分子量: 253.26
• InChiKey: ZUNUKXBPIUPHMZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  phenyl N-(imidazo[1,2-a]pyridin-8-yl)carbamate 、 4-[(2S)-2-methylpiperazin-1-yl]-1-methylpyrazolo[3,4-b]pyridin-6-amine 在 N,N-二异丙基乙胺 作用下， 以 乙腈 为溶剂， 反应 2.0h， 以74%的产率得到(3S)-4-(6-amino-1-methylpyrazolo[3,4-b]pyridin-4-yl)-N-(imidazo[1,2-a]pyridin-8-yl)-3-methylpiperazine-1-carboxamide
  参考文献：
  名称：

  PYRIDAZINONE-AMIDES DERIVATIVES

  摘要：

  本发明涉及公式（I）中R1、Ra、Rb和Z具有claim1中给定的含义的化合物，以及它们在预防和治疗疾病中的用途。

  公开号：

  US20150376167A1
• 作为产物：
  描述：

  氯甲酸苯酯 、 咪唑并[1,2-a]吡啶-8-胺 在 吡啶 作用下， 以 乙腈 为溶剂， 反应 4.0h， 以54%的产率得到phenyl N-(imidazo[1,2-a]pyridin-8-yl)carbamate
  参考文献：
  名称：

  [EN] HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE
  [FR] MODULATEURS À BASE D'URÉE À SUBSTITUTION HÉTÉROARYLE D'AMIDE D'ACIDE GRAS HYDROLASE

  摘要：

  描述了某些杂环取代的哌啶基和哌嗪基脲化合物，这些化合物可用作FAAH抑制剂。这些化合物可用于制备药物组合物，并用于治疗由脂肪酸酰胺水解酶（FAAH）活性介导的疾病状态、紊乱和症状，如焦虑、疼痛、炎症、睡眠障碍、进食障碍、胰岛素抵抗、糖尿病、骨质疏松症和运动障碍（例如多发性硬化）。

  公开号：

  WO2010068452A1

文献信息

• [EN] HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE<br/>[FR] MODULATEURS D'URÉE SUBSTITUÉS PAR HÉTÉROARYLE D'AMIDE D'ACIDE GRAS HYDROLASE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2010068453A1

  公开（公告）日：2010-06-17

  Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis).

  描述了某些杂环取代的哌啶基和哌嗪基脲化合物，这些化合物可用作FAAH抑制剂。这些化合物可用于制备药物组合物，并用于治疗由脂肪酸酰胺水解酶（FAAH）活性介导的疾病状态、紊乱和症状，如焦虑、疼痛、炎症、睡眠障碍、进食障碍、胰岛素抵抗、糖尿病、骨质疏松症和运动障碍（例如多发性硬化）。
• HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE
  申请人：Breitenbucher J. Guy

  公开号：US20110230490A1

  公开（公告）日：2011-09-22

  Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis).

  本文描述了某些杂环取代的哌啶基和哌嗪基脲类化合物，可用作FAAH抑制剂。这些化合物可用于制备药物组合物和治疗疾病、紊乱和由脂肪酰胺水解酶（FAAH）活性介导的病状，例如焦虑、疼痛、炎症、睡眠障碍、进食障碍、胰岛素抵抗、糖尿病、骨质疏松症和运动障碍（例如多发性硬化症）的方法。
• Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
  申请人：Breitenbucher J. Guy

  公开号：US08461159B2

  公开（公告）日：2013-06-11

  Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis).

  本文描述了某些杂环芳基取代的哌啶基和哌嗪基脲类化合物，可用作FAAH抑制剂。这些化合物可用于制备药物组合物和治疗由脂肪酸酰胺水解酶（FAAH）活性介导的疾病状态、疾病和症状的方法，如焦虑、疼痛、炎症、睡眠障碍、进食障碍、胰岛素抵抗、糖尿病、骨质疏松症和运动障碍（例如多发性硬化症）等。
• HETEROARYL SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US20140066412A1

  公开（公告）日：2014-03-06

  Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis).

  本文描述了某些杂环取代的哌啶基和哌嗪基脲化合物，它们可用作FAAH抑制剂。这些化合物可用于药物组合物和治疗由脂肪酰胺水解酶（FAAH）活性介导的疾病状态、紊乱和病况的方法，例如焦虑、疼痛、炎症、睡眠障碍、进食障碍、胰岛素抵抗、糖尿病、骨质疏松症和运动障碍（例如多发性硬化症）。
• Heteroaryl urea inhibitors of fatty acid amide hydrolase: Structure–mutagenicity relationships for arylamine metabolites
  作者：Mark S. Tichenor、John M. Keith、William M. Jones、Joan M. Pierce、Jeff Merit、Natalie Hawryluk、Mark Seierstad、James A. Palmer、Michael Webb、Mark J. Karbarz、Sandy J. Wilson、Michelle L. Wennerholm、Filip Woestenborghs、Dominiek Beerens、Lin Luo、Sean M. Brown、Marlies De Boeck、Sandra R. Chaplan、J. Guy Breitenbucher

  DOI：10.1016/j.bmcl.2012.10.076

  日期：2012.12

  The structure-activity relationships for a series of heteroaryl urea inhibitors of fatty acid amide hydrolase (FAAH) are described. Members of this class of inhibitors have been shown to inactivate FAAH by covalent modification of an active site serine with subsequent release of an aromatic amine from the urea electrophile. Systematic Ames II testing guided the optimization of urea substituents by defining the structure-mutagenicity relationships for the released aromatic amine metabolites. Potent FAAH inhibitors were identified having heteroaryl amine leaving groups that were non-mutagenic in the Ames II assay. (C) 2012 Elsevier Ltd. All rights reserved.